136 related articles for article (PubMed ID: 29742075)
1. The timing of molecular imaging in prostate cancer.
Morris MJ
Clin Adv Hematol Oncol; 2018 Mar; 16(3):195-197. PubMed ID: 29742075
[No Abstract] [Full Text] [Related]
2. Targeted PET imaging for prostate-specific membrane antigen in prostate cancer.
Hope TA; Aggarwal RR; Westphalen AC; Cooperberg MR; Greene KL
Future Oncol; 2016 Nov; 12(21):2393-2396. PubMed ID: 27453303
[No Abstract] [Full Text] [Related]
3. Multiparametric Prostate MR Imaging: Impact on Clinical Staging and Decision Making.
Duvnjak P; Schulman AA; Holtz JN; Huang J; Polascik TJ; Gupta RT
Urol Clin North Am; 2018 Aug; 45(3):455-466. PubMed ID: 30031465
[TBL] [Abstract][Full Text] [Related]
4. Clinical Applications of Molecular Imaging in the Management of Prostate Cancer.
Gorin MA; Rowe SP; Denmeade SR
PET Clin; 2017 Apr; 12(2):185-192. PubMed ID: 28267452
[TBL] [Abstract][Full Text] [Related]
5. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
6. Multiparametric Prostate MR Imaging: Impact on Clinical Staging and Decision Making.
Duvnjak P; Schulman AA; Holtz JN; Huang J; Polascik TJ; Gupta RT
Radiol Clin North Am; 2018 Mar; 56(2):239-250. PubMed ID: 29420979
[TBL] [Abstract][Full Text] [Related]
7. Molecular Imaging for Primary Staging of Prostate Cancer.
Pomykala KL; Farolfi A; Hadaschik B; Fendler WP; Herrmann K
Semin Nucl Med; 2019 Jul; 49(4):271-279. PubMed ID: 31227050
[TBL] [Abstract][Full Text] [Related]
8. Molecular imaging of prostate cancer.
Boustani AM; Pucar D; Saperstein L
Br J Radiol; 2018 Apr; 91(1084):20170736. PubMed ID: 29243485
[TBL] [Abstract][Full Text] [Related]
9. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
[TBL] [Abstract][Full Text] [Related]
10. Functional and molecular imaging: applications for diagnosis and staging of localised prostate cancer.
Turkbey B; Mena E; Aras O; Garvey B; Grant K; Choyke PL
Clin Oncol (R Coll Radiol); 2013 Aug; 25(8):451-60. PubMed ID: 23722008
[TBL] [Abstract][Full Text] [Related]
11. Molecular Imaging and Theranostics-A Multidisciplinary Approach.
Farolfi A; Lima GM; Oyen W; Fanti S
Semin Nucl Med; 2019 Jul; 49(4):247-254. PubMed ID: 31227048
[TBL] [Abstract][Full Text] [Related]
12. In vivo visualization of somatostatin receptor expression with Ga-68-DOTA-TATE PET/CT in advanced metastatic prostate cancer.
Alonso O; Gambini JP; Lago G; Gaudiano J; Quagliata A; Engler H
Clin Nucl Med; 2011 Nov; 36(11):1063-4. PubMed ID: 21975409
[No Abstract] [Full Text] [Related]
13. Molecular imaging of prostate cancer with PET.
Jadvar H
J Nucl Med; 2013 Oct; 54(10):1685-8. PubMed ID: 24084704
[TBL] [Abstract][Full Text] [Related]
14. What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer.
Ballas LK; de Castro Abreu AL; Quinn DI
J Nucl Med; 2016 Oct; 57(Suppl 3):6S-12S. PubMed ID: 27694176
[TBL] [Abstract][Full Text] [Related]
15. Imaging on nodal staging of prostate cancer.
Kilcoyne A; Price MC; McDermott S; Harisinghani MG
Future Oncol; 2017 Mar; 13(6):551-565. PubMed ID: 27785926
[TBL] [Abstract][Full Text] [Related]
16. Choline PET/CT for imaging prostate cancer: an update.
Kitajima K; Murphy RC; Nathan MA
Ann Nucl Med; 2013 Aug; 27(7):581-91. PubMed ID: 23632880
[TBL] [Abstract][Full Text] [Related]
17. The phytological future of prostate cancer staging: PSMA-PET and the dandelion theory.
Sathianathen NJ; Geurts N; Nair R; Lawrentschuk N; Murphy DG; Lamb AD
Future Oncol; 2017 Aug; 13(20):1801-1807. PubMed ID: 28762288
[TBL] [Abstract][Full Text] [Related]
18. Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment.
Jadvar H; Ballas LK; Choyke PL; Fanti S; Gulley JL; Herrmann K; Hope TA; Klitzke AK; Oldan JD; Pomper MG; Rowe SP; Subramaniam RM; Taneja SS; Vargas HA; Ahuja S
J Nucl Med; 2020 Apr; 61(4):552-562. PubMed ID: 32238495
[No Abstract] [Full Text] [Related]
19. Detection of prostate cancer relapse with PET/CT using a novel radiotracer.
Lilleby W; Willoch F; Stensvold A
Acta Oncol; 2012 Mar; 51(3):397-9. PubMed ID: 21936756
[No Abstract] [Full Text] [Related]
20. Choline PET/CT for prostate cancer: main clinical applications.
Fuccio C; Rubello D; Castellucci P; Marzola MC; Fanti S
Eur J Radiol; 2011 Nov; 80(2):e50-6. PubMed ID: 20800404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
